Newsletter Tool

Today’s Big News

Jun 6, 2025

'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape

As the investor pendulum swings away from cell therapy, Immatics CEO focuses on raising the bar

Otsuka’s kidney disease drug halves UPCR levels in phase 3 study

TegMine, with ex-Stemcentrx scientists at the helm, bags tech from OBI to help fuel ADC ambitions

Chutes & Ladders—Protara gears up for next steps with commercial pro

Introducing Fierce Medtech's Fierce 15

Featured

'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape

By Darren Incorvaia

At a June 5 cell and gene therapy roundtable hosted by the FDA, Department of Health and Human Services Secretary Robert F. Kennedy Jr. asked the assembled scientists and advocates to provide a list of regulations they’d like to see gone.

As the investor pendulum swings away from cell therapy, Immatics CEO focuses on raising the bar

By Gabrielle Masson

As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: raising the bar for his biotech’s investigational treatment.

Otsuka's kidney disease drug halves UPCR levels in phase 3 study

By James Waldron

Otsuka Pharmaceutical has shared data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio levels.

Precision medicine’s next frontier: unlocking the power of biospecimens

Sponsored by Thermo Fisher Scientific

Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care.

TegMine, with ex-Stemcentrx scientists at the helm, bags tech from OBI to help fuel ADC ambitions

By Nick Paul Taylor

TegMine Therapeutics has secured certain rights to OBI Pharma’s antibody-drug conjugate technology, advancing the efforts of former Stemcentrx scientists to treat cancer by targeting carbohydrates.

Forging the future of cell therapy: Bayer and BlueRock’s unique journey

Chutes & Ladders—Protara gears up for next steps with commercial pro

By Darren Incorvaia,Zoey Becker

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, who brings to the table two decades of industry experience. Before his most recent position as Rafael Holdings’ CEO, Conkling spent over 10 years at Novartis including as commercial lead for the launch of the first ever approved CAR-T therapy, Kymriah, in 2017.

Delivering the Future of Radiopharmaceuticals with Precision

Sponsored by Marken, UPS Healthcare Precision Logistics

Radiopharma is revolutionizing modern medicine. Discover how precision logistics empowers faster, safer delivery of life-impacting therapies when every second counts.

Introducing Fierce Medtech's Fierce 15

By Conor Hale

The companies that make up this class of the Fierce 15 exemplify the idea of moving the field forward by using innovation to build upon what’s come before.

Orca hires ex-Legend exec Gavel to hammer open cell therapy market as CCO

By Nick Paul Taylor

Orca Bio is preparing to make a splash in the cell therapy market. The biotech has hired Steve Gavel as chief commercial officer, securing itself a leader with cell therapy expertise accrued at Legend Biotech and Celgene.

Fierce Pharma Asia—Bispecific field's roller coaster week; Enhertu's first-line win; Regeneron-Hansoh obesity deal

By Angus Liu

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. AstraZeneca and Daiichi Sankyo trotted out Enhertu's detailed data in first-line breast cancer. Regeneron signed on a GLP-1/GIP candidate from Hansoh Pharma. And more.

GOP Senators mull Medicare cuts in bid to get megabill over the finish line: media report

By Noah Tong,Paige Minemyer

As senators seek a path forward for President Trump's "big beautiful bill," Medicare cuts are reportedly on the table, according to media reports. The version of the bill that passed the House in May includes work requirements imposed sooner and changes to state-directed payments, cost-sharing reductions, eligibility checks and gender-affirming care.

Fierce podcasts